NCT06214143招募中1 期
A Single-arm, Multi-center Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety, and Initial Efficacy of T3011 Herpesvirus Injection Combined With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 68
- 试验地点
- 23
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with advanced solid tumors;
- •At least one measurable lesion;
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
- •Expected survival > 12 weeks;
- •Laboratory inspection meets the requirements;
- •For women of childbearing potential, the serum pregnancy test results must be negative prior to the first dose，and effective contraceptive measures must be taken from signing the informed consent form (ICF) until at least 6 months after the last dose;
- •Male subjects of childbearing potential agree to use effective contraception from signing the ICF until at least 6 months after the last dose; In addition, male subjects must agree not to donate sperm during this period;
- •Understand and voluntarily sign the ICF，willing and able to comply with all experimental requirements.
排除标准
- •Subjects who have received other antitumor therapy within the prescribed time prior to the first dose;
- •Subjects with a history of other malignancies within the prescribed time prior to the start of study treatment.
- •At screening, subjects with a history or evidence of high risk cardiovascular disease;
- •Subjects with persistent or active infection requiring intravenous anti-infective therapy;
- •Subjects with autoimmune diseases or a history of autoimmune diseases;
- •Subjects with known psychiatric disorders that may affect trial compliance;
- •Subjects who have pleural effusion, pericardial effusion, or ascites before starting treatment and require puncture drainage, or who had received puncture drainage within the specified time before starting the study treatment;
- •Subjects requiring systemic treatment with anti-HSV drugs during the study period;
- •Subjects who have received live or attenuated vaccines within the prescribed time prior to the first dose, or who plan to receive such vaccines during the study period; Subjects who have received any tumor vaccine in the past;
- •Subjects who had undergone major surgery within the prescribed time before the first dose，and had not recovered from surgery-related adverse reactions or were still in the postoperative recovery period，or who plan to undergo major surgery during the study period;
- •Subjects with a history of drug use，drug abuse or alcohol abuse within the year prior to signing the ICF;
- •Female subjects who are pregnant or breastfeeding, or planning to conceive or have children during the study period;
- •The investigator considers it inappropriate to participate in this study.
研究组 & 干预措施
T3011
Experimental
干预措施: T3011 high dose (Biological)
T3011
Experimental
干预措施: T3011 middle dose (Biological)
T3011
Experimental
干预措施: T3011 low dose (Biological)
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: Approximately 2years
Adverse event type, incidence, duration
Objective response rate(ORR)
时间窗: Approximately 2years
Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1
次要结局
- Progression-free survival (PFS)(Approximately 2years)
- Overall Survival (OS)(Approximately 2years)
- Disease control rate (DCR)(Approximately 2years)
- Duration of remission (DOR)(Approximately 2years)
研究者
研究点 (23)
Loading locations...
相似试验
尚未招募
2 期
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNon Small Cell Lung CancerNCT06620822Shanghai Pulmonary Hospital, Shanghai, China296
尚未招募
2 期
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical StudySquamous Non-Small Cell Lung Cancer SqNSCLCNCT06747169Jian-Guo Zhou, MD, PhD32
尚未招募
2 期
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically RemovedBreast CancerNCT06547476Guangdong Provincial People's Hospital40
招募中
2 期
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric CancerEsophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric AdenocarcinomaNCT05163483Ruihua Xu87
Unknown
2 期
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyTransitional Cell TumorPediatric Solid TumorPediatric CancerLiver CancerHepatoblastomaNCT05322187RenJi Hospital15